Molecular identification of multiple drug resistance (MDR) strain of Mycobacterium tuberculosis
Background and Objectives Isoniazid and rifampin are the first -line drugs against Mycobacterium tuberculosis . Resistance to these important drugs is a serious threat to human public health. Therefore, this study aimed at molecular detection of resistance to these valuable drugs. Materials and meth...
Gespeichert in:
Veröffentlicht in: | Molecular biology reports 2023-12, Vol.50 (12), p.10271-10275 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background and Objectives
Isoniazid and rifampin are the first -line drugs against
Mycobacterium tuberculosis
. Resistance to these important drugs is a serious threat to human public health. Therefore, this study aimed at molecular detection of resistance to these valuable drugs.
Materials and methods
In this descriptive cross-sectional study, 111 non - duplicated clinical samples including sputum and Bronchoalveolar lavage (BAL) samples were collected from patients referred to the Ardabil Health Center between 2017 and 2020. The samples were first examined by microscopic method, then their DNA was extracted using the boiling method. Specific primers and MAS-PCR method were employed for the detection resistance to isoniazid and rifampin drugs and identification of MDR strain.
Results
of 111 specimens, 15.3% belonged to NTM. In total, the resistance rate to isoniazid and rifampin was 17% and 27% respectively while the resistance rate to isoniazid and rifampin among NTM was 61.54% and 38.46%.
Conclusion
In our study, the prevalence of resistance to isoniazid and rifampin among
Mycobacterium tuberculosis
complex(MTC) and non-tuberculous mycobacteria(NTM) was investigated using the MAS-PCR method. This work highlighted the high anti- tuberculosis resistance rate among NTM compared to MTC strains. |
---|---|
ISSN: | 0301-4851 1573-4978 |
DOI: | 10.1007/s11033-023-08867-7 |